Overview

A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

Status:
Not yet recruiting
Trial end date:
2027-12-22
Target enrollment:
Participant gender:
Summary
The main objective of this study is to evaluate the tumor objective response rate (ORR) of sotorasib assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria in participants who receive sotorasib at either Dose A or a Dose B whose tumors are programmed death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) < 1% and/or harbor a serine/threonine kinase 11 (STK11) co-mutation, in a subgroup of subjects with PD-L1 < 1% and in a subgroup of subjects with STK11 co-mutation.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen